Can Glenmark Pharma Capture the $384 Mil US Nasal Spray Market from Haleon?

Synopsis: Glenmark targets a $480 million US opportunity through launches in pain and allergy segments. While milnacipran offers steady niche demand, fluticasone taps a larger OTC market. The strategy strengthens its US portfolio, balancing prescription and consumer healthcare, with growth driven by scale, pricing power, and limited competition in early phases.                  

Glenmark Pharmaceuticals has made its presence in the US stronger by launching two important products in the pain and allergy markets. The company has launched Milnacipran Hydrochloride tablets and gotten approval for Fluticasone Propionate nasal spray. Together, these products target a $480 million market opportunity.

With a market cap of Rs 59,100 crore, the shares of Glenmark Pharmaceuticals Ltd are trading at Rs 2,095 and are trading at a PE of 22 compared to their industry PE of 27.7. The shares have given a return of more than 360% in the last 5 years.

These launches show that Glenmark wants to grow in both prescription generics and over-the-counter (OTC) products. The company wants to build a more diverse and scalable US portfolio by getting into two different therapeutic areas.

Dual Launch Targets Large US Markets

Milnacipran, an authorised generic for Savella that is mostly used to treat fibromyalgia, is the source of the pain segment opportunity. The press release says that IQVIA data shows that this market had sales of about $102.9 million a year. This gives Glenmark access to a small but steady market.

Glenmark’s fluticasone nasal spray, which is similar to Flonase, has been approved by the US FDA for use in people with allergies. This product is available in a much larger market. According to Nielsen data this segment had annual sales of about $384.7 million, which means it is a high-volume opportunity.

Competition and Strategic Positioning

Glenmark competes with well-known companies like Haleon and other generic drug makers in the allergy market. The company’s first over-the-counter nasal spray in the US is a strategic move into consumer healthcare, which can grow through retail distribution.

The launch as an authorised generic gives the company an edge in the pain medication market. These kinds of products usually don’t have much competition at first, which lets Glenmark get a head start in the market. This gives the company an early-entry advantage in a specialised therapy like fibromyalgia, where stable demand is supported by patient continuity.

Business Impact and Growth Outlook

The two launches let Glenmark balance steady prescription demand with high-volume sales of over-the-counter drugs. The allergy segment gives the company more scale and access to a wider range of markets, which increases its overall growth potential. The pain segment, on the other hand, provides steady revenue streams.

Also, Glenmark’s well-established distribution network in the US will be very important for getting people to use the product. If it can offer competitive prices and enter the market quickly, it could further strengthen its position against its competitors.

The company’s entry into the OTC market could lead to new growth opportunities in the long run, and the authorised generic strategy helps the company make money. These launches give Glenmark a chance to explore $480 million in the US market as long as they keep doing a good job.    

Financials

The revenue from operations for the company stood at Rs 3,901 crore in Q3 FY26 compared to the Q3 FY25 revenue of Rs 3,388 crore, up by about 15 per cent YoY. Similarly, the net profit stood at Rs 403 crore in Q3 FY26, up compared to the Rs 348 crore profit in Q3 FY25.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Can Glenmark Pharma Capture the $384 Mil US Nasal Spray Market from Haleon? appeared first on Trade Brains.